Polycythemia vera (PV) is an acquired clonal disorder characterized by increased production of mature red cells and growth of erythroid colonies in the absence of erythropoietin. Mutation of the erythropoietin receptor has been demonstrated to cause familial polycythemia, but no mutations have been found in PV. Moreover, both erythroid and myeloid progenitors from patients with PV have been reported to be hypersensitive to a number of dierent growth factors. Attention has therefore focused on post-receptor signal transduction pathways. The SHP-1 gene is an especially attractive candidate gene. Firstly, SHP-1 binds to and negatively regulates signalling from the erythropoietin receptor and is likely to regulate other cytokine receptors in a similar manner. Secondly, absence of SHP-1 protein in the motheaten mouse is accompanied by increased sensitivity of hematopoietic progenitors to a number of cytokines including erythropoietin. Thirdly, familial or sporadic polycythemia in man may result from mutations of the SHP-1 binding domain of the erythropoietin receptor. We have therefore searched for mutations of the SHP-1 gene in genomic DNA from patients with PV. In this disease the majority of peripheral blood lymphocytes are not part of the malignant clone and a variable proportion of myeloid cells may arise from normal progenitors. We have therefore chosen to study DNA from puri®ed peripheral blood granulocytes obtained from nine women in whom the granulocytes were clonally derived. Southern analysis was used to show that the gene was not rearranged and densitometry con®rmed the presence of two copies of the gene in each DNA sample. Sequencing of the entire coding region and all splice junctions revealed no mutations. Hematopoietic transcription factor binding sites in the SHP-1 promoter region were intact and the methylation status of the two SHP-1 promoters in PV patients was identical to that in three normal controls. Finally, we showed that levels of SHP-1 protein in granulocytes from patients was similar to those from normal controls. These results demonstrate that the SHP-1 gene is structurally and transcriptionally intact in patients with PV.
Polycythemia vera (PV) is an acquired clonal disorder characterized by increased production of mature red cells and growth of erythroid colonies in the absence of erythropoietin. Mutation of the erythropoietin receptor has been demonstrated to cause familial polycythemia, but no mutations have been found in PV. Moreover, both erythroid and myeloid progenitors from patients with PV have been reported to be hypersensitive to a number of dierent growth factors. Attention has therefore focused on post-receptor signal transduction pathways. The SHP-1 gene is an especially attractive candidate gene. Firstly, SHP-1 binds to and negatively regulates signalling from the erythropoietin receptor and is likely to regulate other cytokine receptors in a similar manner. Secondly, absence of SHP-1 protein in the motheaten mouse is accompanied by increased sensitivity of hematopoietic progenitors to a number of cytokines including erythropoietin. Thirdly, familial or sporadic polycythemia in man may result from mutations of the SHP-1 binding domain of the erythropoietin receptor. We have therefore searched for mutations of the SHP-1 gene in genomic DNA from patients with PV. In this disease the majority of peripheral blood lymphocytes are not part of the malignant clone and a variable proportion of myeloid cells may arise from normal progenitors. We have therefore chosen to study DNA from puri®ed peripheral blood granulocytes obtained from nine women in whom the granulocytes were clonally derived. Southern analysis was used to show that the gene was not rearranged and densitometry con®rmed the presence of two copies of the gene in each DNA sample. SequencingIntroduction Polycythemia vera (PV) is a member of the myeloproliferative disorders, an overlapping spectrum of clonal diseases thought to result from the acquisition of mutations by multipotent hematopoietic progenitors Wasserman et al., 1995; Green, 1996) . In PV the abnormalities are predominantly erythroid. The disease is characterised in vivo by an increased number of mature red cells and in vitro by the growth of erythroid colonies in the presence of serum but without added erythropoietin (Prchal and Axelrad, 1974; Eaves and Eaves, 1978; Eridani et al., 1987) .
Erythropoietin is the main physiological regulator of proliferation and dierentiation of erythroid cells (Erslev, 1991; Krantz, 1991) . Several observations link alterations of the erythropoietin receptor with abnormal erythroid proliferation and/or differentiation. In murine systems erythroblastosis induced by the Friend spleen focus forming virus is mediated by an interaction between viral gp55 and the cellular erythropoietin receptor (Li et al., 1990; Zon et al., 1992) . In addition, mutation of codon 129 from arginine to cysteine results in spontaneous receptor homo-dimerisation and erythropoietin-independent proliferation (Watowich et al., 1992; Yoshimura et al., 1990) . In humans two lines of evidence exist. Firstly, familial and sporadic polycythemia may be associated with carboxy-terminal truncations or mutations of the erythropoietin receptor (De La Chapelle et al., 1993; Sokol et al., 1994 Sokol et al., , 1995 . Secondly, erythroleukemic cell lines have been reported to contain mutated erythropoietin receptors (Chretien et al., 1994; Ward et al., 1992; Winkelmann et al., 1995) .
In view of these reports, a number of groups have looked for mutations of the erythropoietin receptor in patients with PV. Hess et al. (1994) used SSCP and sequencing to study cDNA samples generated from bone marrow or peripheral blood mononuclear cells in 24 patients with PV. More recently genomic sequencing of the entire erythropoietin receptor coding region was performed using unfractionated peripheral blood cell DNA from 12 patients with PV (Le Couedic et al., 1996) . Neither study revealed any mutations in the erythropoietin receptor in patients with PV.
These results are consistent with recent insights into the biology of PV. Puri®ed erythroid progenitors and de®ned serum-free culture conditions have been used to show that erythroid progenitors are hypersensitive to several dierent growth factors (Dai et al., 1992 (Dai et al., , 1994 Correa et al., 1994; Dudley et al., 1990) . Furthermore, granulocyte/monocyte and megakaryocyte progenitors also displayed hypersensitivity to some growth factors (Dai et al., 1992; Kobayashi et al., 1993) , a ®nding which accords well with the raised white blood cell and platelet counts often seen in patients with PV. Taken together, these observations suggest that the target gene(s) in PV may lie in a signal transduction pathway that is common to multiple dierent growth factors.
SHP-1 is an intracellular phosphatase which contains two SH2 domains and which is expressed primarily in hematopoietic cells (Plutzky et al., 1992; Matthews et al., 1992; Yi et al., 1992; Banville et al., 1995) . The gene for SHP-1 is a particularly attractive candidate gene in PV for several reasons. Firstly, SHP-1 binds to and negatively regulates the erythropoietin receptor (Ihle, 1995; Ihle et al., 1995) . Cells containing an erythropoietin receptor mutated at the SHP-1 binding site are hypersensitive to erythropoietin and display prolonged erythropoietin-dependent phosphorylation of JAK2 (Klingmuller et al., 1995) . Secondly, SHP-1 binds to several other cytokine receptors (including the IL3b chain and c-kit) and is likely to modulate their activity in a similar manner . Thirdly, familial or sporadic primary polycythemia in man may be associated with erythropoietin receptor alterations which delete or mutate the negative regulatory domain containing the SHP-1 binding site (De La Chapelle et al., 1993; Sokol et al., 1994 Sokol et al., , 1995 . Fourthly, mice with an SHP-1 null mutation (motheaten) or a deletion in the catalytic domain (motheaten viable) display a variety of hematopoietic abnormalities including hypersensitivity of erythroid progenitors to erythropoietin (Green and Shultz, 1975; Shultz et al., 1984 Shultz et al., , 1993 Van Zant and Shultz, 1989; Tsui et al., 1993) .
We have therefore studied in detail the gene for SHP-1 in nine female patients with PV. The HUMARA assay was used to demonstrate that the vast majority of peripheral blood granulocytes were clonal in each patient, thus ensuring that heterozygous alterations would be detected. Granulocyte DNA was used to perform Southern blot analysis, methylation studies and genomic sequencing of the entire coding region and splice junctions. No quantitative or qualitative abnormalities were found. Furthermore, levels of SHP-1 protein in granulocytes from patients were comparable to those from normal controls. These data demonstrate that most cases of PV do not result from alterations of SHP-1
Results

Peripheral blood granulocytes are clonal and T cells polyclonal in all patients
Highly puri®ed granulocyte DNA from nine patients with PV was analysed for the presence of mutations in the SHP-1 gene. The clinical details of the patients are shown in Table 1 . Granulocyte DNA was studied since peripheral blood granulocytes have been previously shown to arise from the transformed progenitor in patients with PV (Asimakopoulos et al., 1994 (Asimakopoulos et al., , 1996 and references therein). These cells may carry cytogenetic abnormalities detectable in bone marrow of patients with this disorder and several reports have demonstrated that granulocytes but not lymphocytes demonstrate unilateral X-inactivation patterns in patients with PV.
However, unilateral X inactivation in granulocytes from some patients with PV is incomplete, implying that in these cases clonal and polyclonal granulocytes co-exist in peripheral blood (Asimakopoulos et al., 1996) . Accurate detection of heterozygous mutations would depend on the majority of granulocytes being clonal. Thus, a heterozygous mutation may be masked by the presence of a substantial subpopulation of normal cells in the sample. We have previously described a method to calculate the percentage of clonal granulocytes from X-chromosome inactivation patterns of puri®ed granulocytes and T cells (Asimakopoulos et al., 1996) . This methodology was used to choose for this study nine female patients with PV. The proportion of clonal granulocytes in peripheral blood exceeded 70% in all cases and in seven patients was greater than 95% ( Figure 1 and Table 1 ).
Sequencing of the SHP-1 coding region and splice junctions Granulocyte DNA from nine patients and one control individual was used for SHP-1 exon ampli®cation. Exons 2 ± 16 were examined for mutations. Exon 1 is not expressed in hematopoietic cells and exon 17 contains untranslated sequences (Banville et al., 1995) . Primers were designed in intronic sequences approximately 60 ± 80 base pairs from the corresponding splice junction. This was to ensure that splice junction sequence would be reliably analysed by the automatic sequencer. Primer sequences and conditions of ampli®cation are given in Table 2 . 
SHP-1 is intact in polycythemia vera FA Asimakopoulos et al Ampli®cation products were visualised and gel puri®ed from 1.5% agarose gels. In all cases the size of fragments ampli®ed from patient DNA appeared the same as the size of fragments ampli®ed from a normal control (data not shown). Subsequently PCR products (including the normal control) were sequenced usinḡ uorescently labelled dideoxy terminators. Resultant sequences from patient samples were compared to the normal control DNA and to the published genomic (Banville et al., 1995) and cDNA sequences (Plutzky et al., 1992) .
Granulocyte DNA from patient EG35 demonstrated a heterozygous pattern at nucleotide position 119 of exon 3 (Figure 2a ). The wild type sense allele contains G in this position but in this patient it co-existed with a novel allele containing A. The wild type codon GTC codes for valine while the novel codon ATC codes for isoleucine. However, polyclonal T cells obtained from the same patient produced the same pattern. Therefore, a polymorphism has been detected at this site. All other patients produced the wild type pattern.
During the course of our analysis, we noted discrepancies between the published genomic (Banville et al., 1995) and cDNA sequences (Plutzky et al., 1992) in ®ve instances. In exon 4, all our patients appeared to lack the same 16 nucleotides starting at position 120 compared to the published genomic sequence (Banville et al., 1995) (Figure 2b ). However, the same sequence was detected in granulocyte DNA from the normal control. Inclusion of these 16 nucleotides would alter the reading frame and predicts a truncated protein the sequence of which does not correspond to the published cDNA and amino acid sequence (Plutzky et al., 1992; Banville et al., 1995) . We therefore conclude that these 16 nucleotides have been inserted by error in the published genomic sequence of exon 4.
There are four further discrepancies between the published genomic (Banville et al., 1995) and cDNA sequence (Plutzky et al., 1992) . In each case, our analysis of ten individuals agreed with either the genomic or cDNA sequence. In accord with the cDNA sequence, we detected a T at position 111 of exon 5 (GTG=valine) and a G at position 57 of exon 6 (GTG=valine), whereas the genomic sequence contains A (GAG=glutamic acid) and A (GTA=valine) at these positions, respectively. Moreover, our analysis agreed with the genomic sequence at position 9 of exon 3 (CTC=leucine) and position 51 of exon 8 (CAG=glutamine), whereas the cDNA sequence features (CAC=histidine) and (CAA=glutamine) at these positions. These dierences may represent rare polymorphisms carried by the discrepant clones.
All splice junctions also appeared intact by sequence analysis. This was an important ®nding since the motheaten viable mutation disrupts a splice donor site
Figure 1 Clonality of peripheral blood granulocytes in PV patients. DNA was extracted from highly puri®ed peripheral blood granulocytes (G) and T cells (T) and ampli®ed using HUMARA primers with (+) or without (7) pre-digestion with the methylation sensitive enzyme HhaI 
Sequencing of the SHP-1 promoter used in hematopoietic cells
The SHP-1 gene possesses two alternative promoters (Banville et al., 1995) (Figure 3a) . Promoter 2 is active in hematopoietic cells whereas Promoter 1 has been found to be active only in cells of non-hematopoietic origin. Mutations in regulatory regions have been previously shown to account for transcriptional inactivation leading to disease, most notably in band d-thalassemias and hemophilia B (Cooper and Krawczak, 1993) . It was therefore conceivable that acquired mutations in Promoter 2 might down-regulate transcription of SHP-1 in hematopoietic cells. We therefore sequenced 520 bp upstream of the transcription initiation site of Promoter 2, a region which contains two GATA motifs as well as single CCAAT, AP-2 and Sp-1 sites. The sequence in all nine patients was identical to that in the normal control and the publicly available sequence (Banville et al., 1995) .
Methylation of promoter regions
Transcriptional silencing of genes containing CpG islands at their 5' ends may be associated with methylation of cytosine residues (Bird, 1992 and references therein). In the case of tumor suppressor genes this mechanism has been shown to account for functional loss of an allele with concominant loss of the other allele by deletion (Herman et al., 1994; Merlo et al., 1995) . The region encompassing promoter 2 and exon 2 of SHP-1 appears particularly CpG rich and we therefore considered the possibility that abnormal methylation (with subsequent silencing) of one or both alleles of the SHP-1 promoter may occur in PV. Granulocyte DNA from three normal controls and all nine patients was therefore digested with HindIII and EcoRI, with or without HpaII and hybridised to a probe containing exons 2 and 3 (Figure 3b) . A 5.6 kb band was observed in the absence of HpaII but was completely replaced by fragments less than 500 bp after Figure 2 Sequencing analysis of SHP-1 coding regions. (a) A heterozygous substitution at position 119 of SHP-1 exon 3 in granulocyte and T cell DNA from patient EG35 is shown (antisense strand). The novel allele contains T in this position. The wild type sequence from a normal control is also shown. (b) Analysis of the sense strand of SHP-1 exon 4 in granulocyte DNA from a normal control demonstrates the correct sequence at in the vicinity of nucleotide 120. In the published genomic sequence (Banville et al., 1995) a 16-nt insertion appears by error in this position. The sequence of the same region in granulocyte DNA from patient AB66 is shown at the bottom panel digestion with HpaII. Moreover, both patients and controls gave rise to the same pattern of low molecular weight fragments in the presence of HpaII. These results demonstrate that at least some of the HpaII sites in the region of Promoter 2 were unmethylated in the three normal controls and that the same methylation pattern was obtained in all nine patients with PV. A similar analysis of promoter 1 demonstrated indistinguishable methylation patterns in patients and controls (Figure 3b) . We conclude that both SHP-1 promoters have similar methylation patterns in granulocytes from PV patients and normal individuals.
Search for haploinsuciency and gene rearrangements
Inadequate levels of SHP-1 expression could also be the result of gene deletion resulting in haploinsuciency. Moreover, the gene could be disrupted by gross rearrangements which would not be detectable by coding region sequence analysis.
To exclude these possibilities granulocyte DNA from eight patients and two controls was digested using HindIII or EcoRI and analysed on Southern blots by hybridisation to a full length SHP-1 cDNA probe. All patient samples produced the same pattern as normal DNA (Figure 4) . Similarly, a probe encompassing exon 1 did not detect any rearrangements in the region containing promoter 1 (data not shown).
Autoradiographic signals were quantitated and compared to those obtained using a control probe from the short arm of chromosome 20 (p4.8) ( Figure  4) . In all patients the optical density ratios obtained were similar to the ratios obtained from control DNA. These experiments demonstrate that the genomic region containing the SHP-1 gene was structurally intact in patients with PV and that both copies of the gene were present in patient DNA.
The SHP-1 gene is functional and capable of producing normal levels of protein in granulocytes from patients with polycythemia vera Although the coding and promoter regions of the SHP-1 gene did not demonstrate sequence alterations, the expression of SHP-1 protein might be abolished as the result of distal cis-acting or trans-acting mutations. To address this possibility, we compared SHP-1 protein levels in granulocytes from PV patients and normal controls using immunoblotting analysis. The results are shown in Figure 5 . In all patients, expression of SHP-1 protein in granulocytes from patients was similar to normal controls.
Discussion
Polycythemia vera is thought to result from mutations aecting a multipotent hematopoietic progenitor. However identi®cation of target gene(s) has proved elusive. Recent studies from several groups have described abnormal responsiveness of erythroid and myeloid progenitors to several dierent growth factors, thus suggesting that critical changes may have occurred within a signal transduction pathway shared by multiple growth factors. SHP-1 represents a prime candidate gene, because biochemical studies suggest that it regulates the activity of the erythropoietin receptor as well as several other cytokine receptors and also because of the biological phenotype of mice with reduced or absent SHP-1 protein. We have therefore undertaken a comprehensive search for abnormalities of the SHP-1 gene in patients with PV.
Patients with myeloproliferative disorders exhibit variable involvement of dierent hematopoietic lineages in the clonal process. In most patients with PV, peripheral blood granulocytes are clonal, but in some patients the granulocytes are polyclonal and in others an intermediate X chromosome inactivation pattern is obtained, suggesting that in these latter (Banville et al., 1995) . A partial restriction map indicating the locations of HindIII (H), EcoRI (R), HpaII (P) and BstXI (X) sites is shown. Pr1 and Pr2 indicate the sites of the alternative SHP-1 promoters. (b) Methylation of SHP-1 promoters. Southern blot analysis of DNA from normal controls and patients with PV. All samples were digested with HindIII and EcoRI, either with (+) or without (7) subsequent digestion with HpaII and hybridised to a Probe A (top panel). This probe includes the coding regions of exons 2 and 3 together with the intervening intronic sequences and was generated using primers and ampli®cation conditions given in Table 2 . In all cases, the detected 5.6 kb band disappears after digestion with HpaII. The ®lter was subsequently stripped and re-probed with probe B (bottom panel). This probe was generated after BstXI digestion of a PCR-generated fragment containing promoter 1 and exon 1 (see Table 2 and restriction map on a). Lanes 1 ± 2, 3 ± 4 and 5 ± 6 contain DNA from each control; Lane 7, patient AB66; Lane 8, patient WG03; Lane 9, patient EG35; Lane 10, patient KG12; Lane 11, patient VG33; Lane 12, patient JK86; Lane 13, patient MM49; Lane 14, patient GP63; Lane 15, patient EP94. All patient DNAs are digested with EcoRI and HindIII followed by HpaII patients only a proportion of granulocytes are clonally derived (Asimakopoulos et al., 1996; Gilliland et al., 1991) . We therefore used the HUMARA assay to screen female patients and have chosen to study nine women in whom the vast majority of peripheral blood granulocytes were clonal. In each case peripheral blood T cells displayed a polyclonal pattern. T cell DNA could therefore be used as a source of constitutional DNA.
Exons 2 ± 16 were ampli®ed from granulocyte DNA in each patient using an error-proof thermostable DNA polymerase. Exon 1 is not expressed in hematopoietic cells. Sequence analysis of the entire coding region of all nine patients was compared to that obtained from a normal control. In eight patients, the sequences were identical to the control sequence. One patient displayed a polymorphism that resulted in a conservative amino acid substitution. During our analysis we noted four discrepancies between the published genomic (Banville et al., 1995) and cDNA (Plutzky et al., 1992) sequences. Our analysis agreed with the genomic sequence in two cases and with the cDNA sequence in the remaining two instances. Since the sequence presented here was identical at these positions in all ten individuals studied, the discrepancies may represent rare polymorphisms. Since the motheaten viable phenotype results from a point mutation in a splice donor, particular care was taken to sequence splice junctions. However, no splice junction mutations were found. These data demonstrate that most cases of PV do not result from alterations of the coding region or splice junctions of SHP-1.
Sequencing of individual exons only reveals the structure of relatively small stretches of sequence and does not give any clues about the overall integrity of a locus. Thus it is possible that, although coding regions appear intact, the gene may be inactivated as the result of major genomic rearrangements. Southern blotting was therefore used to investigate this possibility. Hybridisation of a full length SHP-1 cDNA probe to DNA digested using two dierent restriction enzymes produced identical patterns in all patient samples and two normal controls. These results demonstrate that the gene was not inactivated as the result of gross rearrangement, but do not exclude a gene dosage eect. Haploinsuciency for critical genes underlies many developmental disorders (Fisher and Scambler, 1994) and it was therefore plausible that deletion of an entire SHP-1 allele might in¯uence the behavior of hematopoietic progenitors. However, densitometric analysis of Southern blots demonstrated that both copies of the SHP-1 gene were present in all patients.
Reduced levels of SHP-1 may also result from transcriptional inactivation, secondary to promoter mutation or methylation. The hematopoietic promoter of the SHP-1 gene was therefore sequenced in all patients and was found to contain no mutations. Methylation of promoter regions has been associated with transcriptional silencing, most notably in the case of tumor suppressor genes p16 and VHL (Herman et al., 1994; Merlo et al., 1995) . We therefore compared the methylation status of the two SHP-1 alternative promoters in granulocytes from patients and from three normal controls. Both SHP-1 promoters in PV granulocytes were at least partially unmethylated and displayed the same pattern as normal controls. Finally, we considered the possibility that mutations in distal cis-acting elements or trans-acting eects may abolish SHP-1 expression in patients with PV. We therefore used immunoblotting to demonstrate comparable levels of SHP-1 protein in granulocytes from PV patients and normal controls. These results demonstrate that clonally derived granulocytes from patients with PV contain the cis-and trans-acting elements necessary for expression of the SHP-1 protein.
Taken together, our results demonstrate that most cases of PV do not result from alterations in the SHP-1 gene. Further studies of other candidate genes are now required.
Materials and methods
Patients
Peripheral blood samples from nine female patients with polycythemia vera were studied (Table 1 ). All samples were obtained from patients attending Addenbrookes Hospital, Cambridge or St. Thomas' Hospital, London. Diagnosis of polycythemia vera was established according to the Polycythemia Vera Study Group (PVSG) criteria.
Cell separation
Highly puri®ed granulocytes were prepared from peripheral blood using density gradient centrifugation. 10 ± 20 ml of EDTA-anticoagulated blood was layered onto Histopaque 1077 cushions. Red cells from the resultant high-density cell pellets were lysed using an alkaline lysis method. The purity of granulocyte preparations was assessed on cytospins and was in each case greater than 97%. High molecular weight DNA was extracted from granulocyte pellets according to standard methods.
Cells from the mononuclear fraction were washed in PBS/ 0.1% BSA and incubated with anti-CD2 conjugated magnetic beads (Dynabeads, Dynal, Oslo, Norway) according to manufacturer's recommendations. In each case the percentage of dynabead-bound cells was determined after each separation procedure using a counting chamber. This was routinely in the range of 90 ± 100%. Cells were suspended in sterile autoclaved water at a concentration of 10 5 cells/ml, boiled for 5 min and stored at 7808C until required. For clonality assays, granulocyte preparations were subjected to a further immunomagnetic separation step using anti-CD15 conjugated Dynabeads.
HUMARA clonality assay
Aliquots of 10 000 dynabead-separated cells in 100 ml of water were phenol chloroform extracted and the DNA precipitated using glycogen as carrier. DNA pellets were resuspended in 14 ml of 16 HhaI buer and 40 units of enzyme added. Reactions were left to proceed at 378C overnight. Digested DNA was then added to a ®nal volume of 30 ml of PCR mixtures containing buer (50 mM KCl, 10 mM Tris HCl pH 8.3, 1.5 mM MgCl 2 , 0.1% gelatine), dNTPs (125 mM each), primers (25 pmol each) and Taq polymerase (0.5 units). In each reaction mixture 1/10 of one of the primers was end labelled with 32 P dATP using polynucleotide kinase. Samples were ampli®ed in an MJ Research programmable thermal controller for 30 cycles (948C for 40 s; 658C for 30 s; 728C for 30 s) with an initial denaturation (948C, 5 min) and a ®nal extension step (728C, 15 min). Products were analysed on 8 M urea, 6% polyacrylamide gels followed by autoradiography. Band densities were measured on autoradiographic ®lms using NIH Image Analysis Software vs 1.57 (this software is in the public domain and available through the Internet). The method used to calculate the percentage of clonal granulocytes from allele intensity ratios has been described previously (Asimakopoulos et al., 1996) .
PCR ampli®cation of SHP-1 exons
To avoid misincorporations during PCR, a high ®delity thermostable DNA polymerase with 3' to 5' exonuclease (proofreading) activity (Pfu Polymerase, Stratagene) was used to generate PCR fragments for sequencing. 200 ng of genomic DNA were added to PCR reactions containing 16Pfu polymerase buer (Stratagene), 200 mM of each dNTP, 1 mM of each forward and reverse primer and 2.5 U cloned Pfu polymerase (Stratagene). Primer sequences as well as reaction conditions are given in Table 2 . PCR fragments were gel-puri®ed from 1.5% agarose gels using the QUIEX gel puri®cation kit (Quiagen).
The publicly available genomic sequence upstream of exon 5 (Banville et al., 1995) was not adequate to design primers at the desired distance from the 5' splice acceptor site. In order to generate additional sequence data at this region we used a full length SHP-1 cDNA probe to screen a human PAC library (Ioannou et al., 1994) . Five clones from a total of about 130 000 were positive. Each of these clones was grown in stab cultures. A loopful of cells from each clone was added to PCR reaction mixtures containing a forward primer from the coding region of exon 4 and a reverse primer from the coding region of exon 5. This resulted in ampli®cation of a 2.7 kb fragment corresponding to the long intron separating exons 4 and 5. This ampli®cation had not been previously possible using genomic DNA. Using the ampli®ed fragment approximately 200 bp of sequence were obtained upstream of exon 5 and these were used to design a forward primer in proximity to the splice acceptor.
Fluorescent sequencing
Puri®ed PCR fragments were added to reaction mixtures containing¯uorescently labelled dideoxy chain terminators (ABI Prism Dye Terminator Kit, Perkin Elmer) and processed according to the manufacturer's recommendations. Reactions were run on 8 M urea, 6% polyacrylamide, 16TBE gels on a 373A ABI Sequencer. Data were analysed using SeqEd software (Applied Biosystems).
DNA extraction and quantitative Southern blotting analysis
High molecular weight DNA from granulocytes was digested with restriction enzymes, electrophoresed in 0.8% agarose gels in 16 TBE and blotted onto Hybond N+ nylon membranes using capillary transfer. The DNA was alkali ®xed on the membranes and hybridised to 50 ng of 32 P labelled probe DNA. The probe was a full length SHP-1 cDNA clone (Plutzky et al., 1992) . A probe from the short arm of chromosome 20 (p4.8) was used for control hybridisations (Asimakopoulos et al., 1994) . Membranes were washed at high stringency (0.26SSC, 0.1% SDS, 2615 min at room temperature, 1615 min at 65 ± 688C) and exposed to autoradiographic ®lm.
Band intensities on the ®lm were measured using the NIH Image Analysis software. The optical density ratio for each marker was calculated by dividing the relevant band density with the band density for the control probe (p4.8) on the same ®lter. The resultant values were then normalised by comparison to the OD ratio obtained following hybridisation of the same probes to DNA from the normal controls.
Immunoblotting of SHP-1 protein 10 7 granulocytes were lysed on ice in 500 ml NP40 lysis buer (1% Nonidet NP40, 50 mM Tris HCl pH 7.5, 10 mM EDTA, 80 mM KCl, containing 50 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mg/ml antipain, 1 mg/ml pepstatin A, 1 mg/ml chymostatin). The particulate fraction was removed by brief centrifugation at 13 000 g. For immunoblots proteins were separated by 10% SDS ± PAGE, electrotransferred to PVDF membrane (Immobilon P), blocked with 3% BSA-5% FCS and immunoblotted with polyclonal rabbit anti-SHP-1 and HRP-linked mouse anti-rabbit IgG. Anti-SHP-1 antibody was developed by immunizing rabbits with a GST-SHP-1 fusion protein (Plutzky et al., 1992) and was subsequently anity puri®ed. Antibody was visualised by chemiluminescent assay according to manufacturers' instructions (Amersham ECL). Identical amounts of total lysate were loaded onto a second 10% SDS ± PAGE gel and protein levels determined by Coomassie Blue staining.
